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Abstract
The impact of cycle completion rates of oxaliplatin-based adjuvant chemotherapy for stage
III colon cancer in real-world practice is unknown.We assessed its impact, and that of treat-
ment modification, on 3-year cancer-specific mortality. Four thousand one hundred and
forty-sevenpatientswithpathological stage III colon cancerundergoingmajor resection from
2014 to 2017 in the English National Health Service were included. Chemotherapy data
came from linked national administrative datasets. Competing risk regression analysis for 3-
year cancer-specific mortality was performed according to completion of <6, 6-11, or 12 5-
fluoropyrimidine and oxaliplatin (FOLFOX) cycles, or <4, 4-7, or 8 capecitabine and
oxaliplatin (CAPOX) cycles, adjusted for patient, tumour and hospital-level characteristics.
Median age was 64 years. Thirty-two per cent of patients had at least one comorbidity.
Forty-two per cent of patients had T4 disease, and 40% hadN2 disease. Compared to com-
pletion of 12 FOLFOX cycles, cancer-specific mortality was higher in patients completing
<6 cycles [subdistribution hazard ratios (sHR) 2.17; 95% CI 1.56-3.03] or 6-11 cycles (sHR
1.40; 95% CI 1.09-1.78) (P < .001). Compared to completion of 8 CAPOX cycles, cancer-
specific mortality was higher in patients completing <4 cycles (sHR 2.02; 95% CI 1.53-2.67)
or 4-7 cycles (sHR 1.63; 95% CI 1.27-2.10) (P < .001). Dose reduction and early oxaliplatin
discontinuation did not impact mortality in patients completing all cycles. Completion of all
cycles of chemotherapy was associated with improved cancer-specific survival in real-world
practice. Poor prognostic factors may have affected findings, however, patients completing
<50% of cycles had poor outcomes. Clinicians may wish to facilitate completion with treat-
mentmodification in those able to tolerate it.
Abbreviations: CAPOX, capecitabine and oxaliplatin; CI, confidence interval; FOLFOX, 5-fluoropyrimidine and oxaliplatin; HES-APC, Hospital Episode Statistics Admitted Patient Care; ICD-10,
International Classification of Diseases 10th edition; IMD, Index of Multiple Deprivation; IMDQ, Index of Multiple Deprivation Quintile; NBOCA, National Bowel Cancer Audit; NHS, National
Health Service; ONS, Office for National Statistics; OPCS-4, Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures, fourth revision; RCT, randomised
controlled trial; SACT, systemic anticancer therapy; sHR, subdistribution hazard ratios.
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What's New
Adjuvant chemotherapy following curative surgical resection is an established treatment for
stage III colon cancer. However, many patients do not complete the planned duration of chemo-
therapy. This is the largest cohort study in real-world practice to evaluate cancer-specific sur-
vival according to the cycle completion rate of oxaliplatin-based adjuvant chemotherapy in
stage III colon cancer patients, and the first to assess the impact of treatment modification strat-
egies. The results show that patients who do not complete their planned cycles have signifi-
cantly poorer outcomes. In the absence of demonstrated negative impacts, clinicians could use
treatment modifications to facilitate completion of adjuvant chemotherapy.
1 | INTRODUCTION
Adjuvant chemotherapy after a planned curative surgical resection for
stage III colon cancer is an established treatment.1,2 However, many
patients do not complete the planned duration of chemotherapy, even
in clinical trials, and in real-world practice this proportion is even
higher with non-completion rates reported as high as 45%.3,4 The
impact of not completing adjuvant oxaliplatin-based chemotherapy on
patient outcomes in real-world practice is unknown.
FOLFOX and CAPOX have been shown in RCTs to improve out-
comes compared to fluoropyrimidines alone.5-7 After publication of
this data, standard practice involved 6 months of adjuvant chemother-
apy (8 cycles of CAPOX or 12 cycles of FOLFOX). However, long-
term morbidity, in particular cumulative neurotoxicity associated with
oxaliplatin-based chemotherapy, is concerning.5
The recent IDEA collaborative study sought to establish the
impact of reducing treatment duration by comparing 6 months treat-
ment to 3 months (4 cycles of CAPOX or 6 cycles of FOLFOX).8,9
Although the study failed to demonstrate overall noninferiority of a
reduced target of 3 months of oxaliplatin-based chemotherapy, sub-
group analysis suggested that 3 months of CAPOX, particularly in
patients with low-risk disease, may be as effective as 6 months with
reduced toxicity. The study found that those prescribed FOLFOX, or
with high-risk disease, may still benefit from longer target durations.8-10
Evidence comparing the efficacy of different target durations of adju-
vant chemotherapy comes from high quality, large RCTs.5,11,12 RCTs,
however, include highly selected patient populations under rigorously
controlled conditions, generally underrepresenting elderly, frail and comor-
bid patients. One study showed that 59% of stage II or III colon cancer
patients in a real-world setting would not be eligible for RCT inclusion.13
Population-based studies, using data such as electronic healthcare records,
are needed to assess the effectiveness of actual durations of adjuvant
chemotherapy on outcomes in diverse non-selected populations under
routine clinical conditions to complement trial findings.14-18
To date, observational studies evaluating the impact of cycle comple-
tion rates for oxaliplatin-based adjuvant chemotherapy on survival for colon
cancer have been limited by a lack of accountability for important con-
founders, and their small sample size (most have fewer than 500 patients).19
In addition, previous studies have not evaluated the survival impacts of
treatment modifications (eg, dose reductions) which aim to reduce toxicity
and support completion of the target duration of therapy.
In this national population-based study using linked administra-
tive datasets, we assessed the impact of the cycle completion rate of
oxaliplatin-based adjuvant chemotherapy on cancer-specific survival
for stage III colon cancer patients treated in the English NHS, account-
ing for important confounders in the largest observational study to
date. In addition, the effects of treatment modification on cancer-
specific survival, namely dose reduction and early discontinuation of
oxaliplatin, were analysed.
2 | METHODS
2.1 | Study population
Our study used NBOCA data,20 HES-APC21 and SACT data22 linked
at patient-level.
2.1.1 | National Bowel Cancer Audit
NBOCA is a prospective mandatory database for all newly diagnosed
colorectal cancer patients in the English NHS. Patients aged 18 years
and above with a primary diagnosis of colon cancer, according to ICD-
10 code C18, undergoing major resection between June 1, 2014 and
April 30, 2017 with pathological stage III colon cancer were identified
in the NBOCA database. Cancers of the appendix were excluded.
2.1.2 | Hospital episode statistics admitted
patient care
HES-APC is an administrative dataset of all admissions to English
NHS hospitals. Inpatient and day case chemotherapy use is captured
via clinical coding, primarily through dedicated OPCS-4 codes,23 with
chemotherapy-related ICD-10 codes also available.24
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2.1.3 | Systemic anticancer therapy database
SACT is a dedicated chemotherapy dataset held by the National
Cancer Registry and Analysis Service.25 Data collection is largely done
via electronic prescribing systems. It includes the capture of detailed
drug-level information such as administration date, drug name, dose,
and administration route for each cycle of chemotherapy. SACT
records chemotherapy administered in any inpatient, day case, outpa-
tient, or community setting.22
SACT and HES-APC data from June 30, 2014 until April
30, 2018 were used because not all English NHS chemotherapy
providers were submitting SACT data before that period.22 This
ensured that all patients had a minimum of 12 months SACT and
HES-APC follow-up data from the NBOCA date of surgery to allow
adequate time for adjuvant chemotherapy completion, accounting
for potential delays.
Previously established methods were used to ascertain adjuvant
chemotherapy receipt, regimen, and number of recorded cycles mak-
ing use of the information in both SACT and HES-APC.26 Patients
receiving oxaliplatin-based adjuvant chemotherapy according to either
SACT or HES-APC were included in the analysis (Figure 1).
2.2 | Study outcome and comparison groups
The primary outcome was colorectal cancer-specific death within
3 years from the date of the first cycle of adjuvant chemotherapy.
Date and underlying cause of death were obtained from linkage to
official death records provided by the ONS.27 The date of the latest
available death record was 10th February 2020, at which point
follow-up times were censored.
Levels of completion of chemotherapy cycles were compared,
separately for each regimen. Completion was compared in the groups
<50%, 50%-92%, and 100% (<6 cycles, 6-11 cycles, 12 cycles
FOLFOX and <4 cycles, 4-7 cycles, 8 cycles CAPOX).
Separate subanalyses were undertaken to evaluate two common
treatment modification strategies: dose reduction and early discontin-
uation of oxaliplatin, both stratified by regimen. For these analyses,
only patients completing 12 cycles of FOLFOX or 8 cycles of CAPOX,
and with linked SACT records were included (3375 patients). Dose
reduction is a binary (yes/no) variable within SACT which refers to
dose reduction of “any anti-cancer drug administered at any point in
the regimen after commencement of the regimen".22 Discontinuation
of oxaliplatin was derived from drug-level information.
NBOCA patients undergoing major resection for pathological stage III colon cancer 
between June 1, 2014 and April 30, 2017 in English NHS Trusts
n = 10 280





Inclusion criteria for adjuvant chemotherapy use
• First recorded cycle of chemotherapy administered within 4 months of NBOCA date of surgery
• Gaps of more than 3 months between the administration of consecutive chemotherapy cycles is 
assumed to represent a switch to different line of treatment (ie, palliative)
• Chemotherapy cycles up to 9 months after the first recorded chemotherapy cycle are considered as 
adjuvant chemotherapy to allow for potential delays
• Patients commencing nonstandard ACT regimens are assumed to be receiving palliative treatment
• Patients switching on to nonstandard ACT regimens partway through treatment are assumed to have 
switched to a different line of treatment (ie, palliative) 








F IGURE 1 Flow chart showing
inclusion of patients [Color figure can be
viewed at wileyonlinelibrary.com]
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2.3 | Patient, tumour and hospital-level
characteristics
Data regarding sex, age, pathological staging (TNM staging), opera-
tive date, surgical urgency, performance status,28 and surgical
access were obtained from NBOCA. Comorbidities, socioeconomic
status, and 30-day unplanned readmission data were obtained from
HES-APC.
The Royal College of Surgeons' Charlson comorbidity score was
derived from ICD-10 codes recorded in the HES-APC dataset in any
hospital admissions in the year preceding colon cancer diagnosis. Indi-
vidual records for liver, renal, or cardiac disease were obtained for the
same timeframe.29 Patients were recorded as having an unplanned
30-day readmission if HES-APC showed an emergency admission
within 30 days of surgery.
Socioeconomic status was derived from the IMD which ranks
32 482 geographical areas of England according to their level of depri-
vation across seven domains.30 Patients were allocated to an IMDQ
based on the national ranking of the area corresponding to their
postcode.
Hospital-level characteristics were derived from the hospital per-
forming the surgery according to NBOCA. University teaching hospi-
tals were identified from the Association of United Kingdom
University Hospitals.31 Onsite chemotherapy presence was collected
in an annual national NBOCA survey of colorectal cancer services.32
2.4 | Statistical analysis
Patient, tumour and hospital-level characteristics were compared
using Ҳ2 tests stratified by chemotherapy regimen alone, and then by
regimen and level of completion. The proportion of patients with a
dose reduction and the proportion of patients discontinuing
oxaliplatin early were reported according to regimen type and level of
completion.
As our study evaluates survival outcomes in relation to the com-
pletion of chemotherapy, starting the analysis from initiation of che-
motherapy may introduce bias as patients who die are unable to
receive further cycles of chemotherapy. To account for this, a land-
mark analysis was undertaken.33 This involved the designation of a
period of time, a priori, from a baseline date (initiation of chemother-
apy) to the study start date (the landmark date) known as the expo-
sure period. Patients who died during the exposure period (6 months
after chemotherapy initiation) were excluded from the analysis. A sen-
sitivity analysis was undertaken to include those who died within this
6-month period.
The crude 3-year cumulative incidence of cancer-specific death
was calculated for each regimen, according to the level of completion,
using a competing risks analysis in which other-cause death was the
competing event.34 Fine and Gray35 competing risk regression models
were used to estimate adjusted subdistribution hazard ratios (sHRs)
between levels of completion for each regimen, adjusting for all















































































































































































































































































































































































































































































6 BOYLE ET AL.
The same methodology was used to calculate unadjusted and
adjusted sHRs for the risk of 3-year cancer-specific death in just those
patients completing 100% of cycles, according to whether or not dose
reduction occurred. This was then repeated for early discontinuation
of oxaliplatin.
Missing values for risk-adjustment variables were imputed with
multiple imputation using chained equations, creating 10 datasets and
using Rubin's rules to combine the sHRs across the datasets.36 Wald
tests were used to calculate P values with the significance level set
at .05.
3 | RESULTS
Of the 10 280 patients undergoing major resection with pathological
stage III colon cancer between June 1, 2014 and April 30, 2017, 6012
(58%) went on to receive adjuvant chemotherapy (Figure 1). Of these,
4147 patients received an oxaliplatin-based regimen. The remaining
1865 patients received 5-FU/capecitabine monotherapy and were
excluded from further analyses.
Two thousand three hundred and seventy-one patients (57%)
received CAPOX and 1776 patients (43%) received FOLFOX
(Table 1). The median age for both regimens was 64 years (inter-
quartile range 56-70 years). The cumulative incidence for 3-year
cancer-specific mortality for all patients included in the study was
16.4% (95% CI 15.3%-17.6%).
3.1 | Levels of completion
3.1.1 | FOLFOX
Fifty per cent of patients completed 12 cycles (100%) of FOLFOX,
37% completed 6-11 cycles (50%-92%), and 13% of patients com-
pleted <6 cycles (<50%) (Table 1). Patients completing the least
FOLFOX chemotherapy were more likely to be female (P < .001), have
a history of cardiac (P = .012) or renal disease (P = .042), undergo
emergency surgery (P = .035), and commence chemotherapy within
8 weeks of surgery (P = .025). There was also a suggestion that
patients who were from more deprived areas were less likely to com-
plete chemotherapy, although this was not statistically signifi-
cant (P = .073).
The 3-year cumulative incidence of cancer-specific death in
patients receiving FOLFOX and completing 12 cycles was 15.1% (95%
confidence interval [CI], 12.8%-17.6%), completing 6-11 cycles was
18.2% (95% CI 15.3%-21.3%), and completing <6 cycles was 26.4%
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F IGURE 2 Cumulative incidence curves for colon cancer-specific
death with competing risk of other-cause death according to level of
completion of (A) FOLFOX (n = 1741) and (B) CAPOX (n = 2331)
[Color figure can be viewed at wileyonlinelibrary.com]





incidence (%) (95% CI)
Unadjusted
sHR (95% CI) P value
Adjusted
sHR (95% CI) P value
FOLFOX 1741 <.001 <.001
12 (100%) 880 15.1 (12.8-17.6) 1.0 1.0
6–11 (50%-92%) 647 18.2 (15.3-21.3) 1.24 (0.99-1.55) 1.40 (1.09-1.78)
<6 (<50%) 214 26.4 (20.6-32.5) 1.87 (1.38-2.54) 2.18 (1.56-3.03)
CAPOX 2331 <.001 <.001
8 (100%) 1166 12.0 (10.2-14.0) 1.0 1.0
4-7 (50%-92%) 809 18.2 (15.6-21.0) 1.60 (1.25-2.06) 1.63 (1.27-2.10)
<4 (<50%) 356 19.8 (15.8-24.1) 1.77 (1.33-2.34) 2.02 (1.53-2.67)
Note: Bold values denote P values .05 and deemed statistically significant.
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The adjusted competing risk regression analysis showed that the
risk of 3-year cancer-specific death in patients completing <6 cycles
or 6-11 cycles of FOLFOX was up to twice as high (P < .001) as those
completing 12 cycles (Tables 2 and S1).
3.1.2 | CAPOX
Forty-nine per cent of patients completed 8 cycles (100%) of CAPOX,
35% completed 4-7 cycles (50%-92%), and 16% of patients completed
<4 cycles (<50%) (Table 1). Patients completing the least CAPOX che-
motherapy were more likely to be older (P < .001) and have less
advanced N-stage disease (P = .027). There was also a suggestion that
patients with a history of liver disease were less likely to complete
CAPOX chemotherapy, although this was not statistically signifi-
cant (P = .073).
The 3-year cumulative incidence of cancer-specific death in those
receiving CAPOX and completing 8 cycles was 12.0% (95% CI 10.2%-
14.0%), completing 4-7 cycles was 18.2% (95% CI 15.6%-21.0%), and
completing <4 cycles was 19.8% (95% CI 15.8%-24.1%) (Figure 2b).
After adjustment, the risk of 3-year cancer-specific death in those
completing <4 cycles or 4-7 cycles was up to twice as high (P < .001)
as those completing 8 cycles (Tables 2 and S2).
3.2 | Treatment modification
3.2.1 | FOLFOX
In the 747 patients completing all cycles of FOLFOX, 47% had a dose
reduction and 60% discontinued oxaliplatin early (Table S3). The
adjusted risk of 3-year cancer-specific death in patients with dose
reduction showed a trend towards lower mortality rates compared to
those receiving the full dose; however, this was not statistically signifi-
cant (sHR 0.70; 95% CI 0.46-1.07; P = .096) (Table 3). Similar findings
were observed for the adjusted 3-year cancer-specific death in
patients discontinuing oxaliplatin early compared to those completing
the oxaliplatin component (sHR 0.72; 95% CI 0.48-1.09; P = .120)
(Table 3).
3.2.2 | CAPOX
In the 941 patients completing all cycles of CAPOX who had linked
SACT data, 48% had a dose reduction and 37% discontinued
oxaliplatin early (Table S3). The adjusted risk of 3-year cancer-specific
death in those receiving a reduced dose was similar to those receiving
the full dose, although the confidence interval was wide (sHR 0.92;
95% CI 0.62-1.34; P = .651) (Table 3). The adjusted risk of 3-year
cancer-specific death in those discontinuing oxaliplatin early was simi-
lar to those completing it although, again, the confidence interval was
wide (sHR 0.84; 95% CI 0.55-1.28; P = .414) (Table 3).
The sensitivity analyses including those patients who died within
6 months of their first chemotherapy dose did not show any signifi-
cant differences in results (not presented).
4 | DISCUSSION
This is the largest cohort study of real-world practice to date evalu-
ating cancer-specific survival according to the cycle completion
rates of oxaliplatin-based adjuvant chemotherapy in stage III colon
cancer patients, and the first to assess the impact of treatment
modification strategies.
TABLE 3 Three-year cancer-specific death according to dose reduction and early discontinuation of oxaliplatin for those completing 100% of






incidence (%) (95% CI)
Unadjusted
sHR (95% CI) P value
Adjusted
sHR (95% CI) P value
FOLFOX
Dose reduction .142 .096
No 396 15.5 (12.1-19.3) 1.0 1.0
Yes 351 11.8 (8.6-15.5) 0.75 (0.50-1.10) 0.70 (0.46-1.07)
Oxaliplatin discontinued .074 .120
No 303 14.0 (10.3-18.3) 1.0 1.0
Yes 455 11.7 (8.9-15.0) 0.71 (0.48-1.03) 0.72 (0.48-1.09)
CAPOX
Dose reduction .330 .651
No 489 11.1 (8.5-14.1) 1.0 1.0
Yes 452 10.5 (7.9-13.6) 0.83 (0.57-1.21) 0.92 (0.62-1.34)
Oxaliplatin discontinued .248 .414
No 608 11.4 (9.0-14.2) 1.0 1.0
Yes 364 9.1 (6.4-12.4) 0.79 (0.54-1.17) 0.84 (0.55-1.28)
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In real-world practice, patients who completed 100% of adjuvant
chemotherapy cycles (12 cycles FOLFOX or 8 cycles CAPOX) had sig-
nificantly improved cancer-specific survival outcomes compared to
those completing fewer cycles. However, in our cohort only half of
patients completed 100% of standard cycles for the timeframe
studied.
Of those completing all cycles, half had a dose reduction, and a
substantial proportion discontinued oxaliplatin early (a third of those
completing all CAPOX cycles and two thirds of those completing all
FOLFOX cycles). However, cancer-specific survival remained similar
in patients completing all cycles, irrespective of any modifications to
their chemotherapy regimen. Patients completing <50% of cycles
(<6 cycles FOLFOX or <4 cycles CAPOX) had much poorer outcomes.
This suggests that completion of adjuvant chemotherapy with treat-
ment modifications rather than early cessation may confer survival
advantages.
4.1 | Strengths and limitations
The main limitation of our study is that, although we found that the
completion of adjuvant chemotherapy is associated with improved
cancer-specific survival, we cannot simply assume a causal relation-
ship. The factors which make patients less likely to complete their
chemotherapy, for example, age and comorbidity, can also make them
less likely to survive. However, the use of cancer-specific survival
reduces the impact that these factors have on survival differences.
Whilst we have adjusted for many confounders (eg, age, comor-
bidity, performance status), we were unable to account for other cau-
ses of chemotherapy discontinuation, for example, patient preference,
psychosocial support, and health behaviours. Despite this, the effect
sizes seen are large and unlikely to be fully explained by residual
confounding.
Second, duration of follow-up was limited by the availability of
SACT data from 2014 onwards and cancer recurrence data was not
available. The implications of this were that we reported 3-year
cancer-specific survival. However, given our early event rate and the
survival differences observed within this shorter timeframe, longer
follow-up is only expected to accentuate our findings. In addition,
approximately 80% of recurrences occur within the first 3 years after
major resection.37
The strengths of our study include using a large, contemporary
and highly representative cohort of patients, which includes all cen-
tres providing colon cancer treatment in the English NHS
(UK) without exclusions, and 95% of eligible patients.20 The patient
and clinical characteristics of our study are comparable to other obser-
vational studies with regards to staging, performance status, surgical
urgency, and time from surgery to adjuvant chemotherapy initia-
tion.38-42 We have also overcome the biases present in previous
observational studies by performing extensive risk-adjustment for
important confounders.19
The study period did not include SCOT trial patients and pre-
ceded publication of the IDEA collaborative results, meaning
treatment duration reflects toxicity or intolerance, rather than patient
or clinician choice informed by these results.8,43 A landmark analysis
was used to exclude patients who died within 6 months of their first
chemotherapy dose (n = 75, 2%).44 This was intended to account for
immortal time bias; patients who died during the time they should
have received chemotherapy would have been unable to complete
treatment. Finally, patients within our cohort were analysed by the
recorded number of chemotherapy cycles in a validated national
curated chemotherapy dataset26 rather than, for example, insurance
or claims data. This has the advantage of using known individual che-
motherapy administration dates compared to, for example, estimating
completion based on the duration between the first and last claims for
chemotherapy without taking account of individual cycles.45
4.2 | Completion and survival
Our adjuvant chemotherapy completion rates of approximately
50% for FOLFOX and CAPOX are comparable to those from previ-
ous observational studies.3,4 They are also plausible compared to
the completion rates of 59% within the SCOT trial for both regi-
mens, given that adherence rates within trial settings are known to
be higher.43 Of interest, completion of the least FOLFOX was asso-
ciated with being female. There has been ongoing debate as to
whether an underlying difference in toxicities exists with 5-FU due
to gender.46 Clinicians should consider this for their own practice
through regimen choice and adequate toxicity prevention mea-
sures, for example, antiemetics. Our study predated the widespread
use of DPYD testing.
High early discontinuation rates were observed in older patients
with around 15%-20% of patients aged 70-79 years completing <50%
of CAPOX or FOLFOX cycles. Based on our study, we are unable to
comment as to whether early stoppage reflects greater toxicity in
older patients, patient preference, or clinician choice. This is because
the completeness of the data item capturing this information in the
SACT dataset was very poor (<20% complete). Given the importance
of completing the target duration, consideration should be made as to
whether monotherapy may be more suitable for elderly patients if this
might support improved compliance.
Several observational studies have demonstrated that patients
who do not complete fluoropyrimidine adjuvant chemotherapy in
real-world practice have less favourable survival outcomes.3,47-49
A recent systematic review and meta-analysis including 20 observa-
tional studies concluded that shortened durations of combination che-
motherapy with CAPOX or FOLFOX may not adversely affect survival.19
However, the findings of this review were limited by the majority of
studies failing to address important confounders such as chemotherapy
regimen, age, sex, tumour site, and stage. We have systematically
addressed these potential confounders in the current study.19 In addi-
tion, many of the studies used outdated data and small sample sizes with
the largest study available in abstract format only.50
The IDEA collaborative study used intention-to-treat analyses to
assess efficacy of two different target durations of adjuvant
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chemotherapy, whereas our study sought to evaluate the impact of
actual completion rates on survival in real-world practice.8 There-
fore, a direct comparison of the two is not appropriate. There is
more relevance to comparing our findings to the per-protocol
results in, for example, the SCOT trial which failed to demonstrate
equivalence in survival (hazard ratio 1.158; 95% CI 1.018-1.317;
P = .64) between patients who actually received 3 vs 6 months of
FOLFOX or CAPOX.43 However, even this is not comparable with
our findings because the national patient cohort included in our
study receiving adjuvant chemotherapy has poorer prognostic fac-
tors than those in trials. For example, patients in our national
cohort are less fit [one-third have a performance status ≥1 (not fully
active) compared to one-fifth within the IDEA study) and have
more advanced disease (41.2% have T4 disease compared to 24.6%
in the IDEA study, and 39.5% have N2 disease compared to 28.6%
in the IDEA study).
Further subanalyses to stratify our findings by low- and high-risk
disease were not possible due to small numbers. After the publication
of the IDEA/SCOT results, surveys have highlighted the ongoing vari-
ation in clinical practice with regards to choice and duration of combi-
nation adjuvant chemotherapy with shifts towards the use of
3 months of treatment for high-risk disease, particularly in the
UK.51,52 We recommend that additional research into the outcomes
and optimal treatment of patients, particularly those with high-risk
disease, is needed.
4.3 | Treatment modification and survival
For patients completing 100% of target cycles, we found that dose
reductions or early discontinuation of oxaliplatin was not associated
with any difference in cancer-specific survival. This has been observed
in other studies, which have demonstrated that reduced dose inten-
sity may not negatively influence survival.53,54 This may reflect the
relative importance of the fluoropyrimdine component of treatment
and the uncertain effect in patients aged 70 and above who constitute
a quarter of our cohort.55,56 We found that between 40%-60% of
patients discontinued their oxaliplatin (depending on regimen), but
continued on a single agent fluoropyrimidine for the rest of their
cycles.
Further analysis of the impact of dose reductions or oxaliplatin
discontinuation in low- and high-risk prognostic groups was limited by
small numbers (reflected in the wide confidence intervals), and an
inability to quantify exact dose reductions.
4.4 | Implications for policy and practice
Current recommendations advise 12 cycles of FOLFOX and suggest
that 4 cycles of CAPOX can be used dependent on other risk factors,
particularly staging.57 Our findings suggest that in real world practice,
once combination chemotherapy has been commenced, completion of
at least 4 cycles of CAPOX or 6 cycles of FOLFOX confers a survival
advantage over early discontinuation.
Unless toxicities are very severe, our data suggests that patients
may benefit from attempting to complete adjuvant chemotherapy
with treatment modifications. Improved strategies to support comple-
tion of chemotherapy might include prompt identification and manage-
ment of chemotherapy-related adverse effects, clear clinician-patient
communication and education, and provision of adequate support to
overcome any physical or psychosocial barriers.
5 | CONCLUSION
Our study demonstrated that in real-world clinical practice only half
of stage III colon cancer patients completed all cycles of their adju-
vant chemotherapy. Patients who do not complete their cycles
were shown to have significantly poorer outcomes. Given that no
negative impacts on survival were demonstrated with treatment
modifications, clinicians may want to use these to facilitate and
encourage completion of adjuvant chemotherapy in those patients
able to tolerate it.
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